SynthesisFrontiers in pharmacology2025
Preclinical evidence for luteolin in ulcerative colitis: a meta-analysis and systematic review.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meta-analysis of plant-derived exosome-like nanoparticles for the treatment of ulcerative colitis: efficacy and mechanisms insights.Frontiers in pharmacology · 2026Pooled it
- Exploring the Potential Mechanism of Zhizhu Decoction in the Treatment of Constipation-Predominant Irritable Bowel Syndrome Through Network Pharmacology and Experimental Validation.Biological procedures online · 2026Article
- Anti-Inflammatory and Antioxidant Effects of Quercetin, Luteolin, and Proanthocyanidins in Canine PBMCs Stimulated withAnimals : an open access journal from MDPI · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Evidence suggests that luteolin (LUT) may offer therapeutic potential in treating ulcerative colitis (UC), though its specific pharmacological mechanisms remain incompletely understood. This meta-analysis aims to assess the pharmacological effects of LUT in UC animal models and investigate its potential mechanisms of action. Methods: A comprehensive search of five databases, namely, PubMed, Web of Science, Embase, EBSCO, and ScienceDirect, was conducted to identify studies investigating the effects of LUT on UC. The search, covering data up to March 2025, yielded 19 eligible studies involving a total of 327 animal subjects. The outcomes were analyzed using the standard mean difference with a 95% confidence interval in R (4.3.3) software. Results: The meta-analysis revealed that LUT significantly ameliorated colon length, reduced the disease activity index, alleviated body weight loss, and decreased histological scores. Further mechanistic analysis indicated that LUT exerts its effects through multiple mechanisms, including the reduction of pro-inflammatory cytokines, elevation of anti-inflammatory cytokines, promotion of tight junction protein expression, and improvement of oxidative stress-related indices. However, LUT appears to have no significant impact on the α-diversity of the intestinal microbiota. Conclusion: This study suggests that LUT may exert significant therapeutic effects in UC animal models through antioxidant, anti-inflammatory, immunomodulatory, and barrier-protective mechanisms. Further clinical studies and translational research are essential to bridge the gap between animal models and human applications. Systematic Review Registration: https://inplasy.com/inplasy-2025-5-0055/, identifier INPLASY202550055.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.